News - idelalisib, Immunologicals

Filter

Current filters:

idelalisibImmunologicals

Popular Filters

1 to 25 of 136 results

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

Emerging therapies for relapsed/refractory CLL/SLL expected to offer efficacy benefits

11-04-2014

The effect of a therapy on overall survival and progression-free survival are attributes that most influence…

BiotechnologyEuropeGilead SciencesidelalisibImbruvicaJohnson & JohnsonMarkets & MarketingOncologyUSA

US FDA approves Stallergenes’ allergy tablet Oralair

US FDA approves Stallergenes’ allergy tablet Oralair

02-04-2014

The US Food and Drug Administration has approved Oralair immunotherapy tablet from French allergen specialist…

ImmunologicalsOralairPharmaceuticalRegulationStallergenesUSA

AnaptysBio and Tesaro team up in $340 million oncology deal

14-03-2014

Therapeutic antibody discoverer AnaptysBio announced a strategic immuno-oncology collaboration with fellow…

AnaptysBioBiotechnologyImmunologicalsLicensingOncologyTesaro

Idelalisib may represent promising treatment for stubborn blood cancers

11-03-2014

A pill that suppresses a key regulator of cancer growth may provide hope to relapsed leukemia and lymphoma…

BiotechnologyGilead SciencesHematologyidelalisibOncologyResearch

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

ALK’s partner for Japan reports positive trial results for house dust mite SLIT-tablet

10-03-2014

Denmark-based allergy specialist ALK Abello said that its Japanese partner Torii Pharmaceutical has reported…

ALK AbelloDenmarkImmunologicalsJapanPharmaceuticalResearchTorii Pharma

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

Tacrolimus Sandoz gets sole subsidy supply status in New Zealand

07-03-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has decided to award immunosuppressant drug…

Asia-PacificGenericsImmunologicalsMarkets & MarketingNew ZealandNovartisPricingSandozTacrolimus Sandoz

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

AAAAI 2014: Merck announces positive results of study in sublingual dust allergen immunotherapy tablet

05-03-2014

Pharma giant Merck & Co has announced results from a Phase IIb study evaluating two doses of its investigational…

ImmunologicalsMerck & CoPharmaceuticalResearchUSA

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

Inovio announces new additions to senior management team

Inovio announces new additions to senior management team

18-02-2014

US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments…

BoardroomImmunologicalsInovio PharmaceuticalsPharmaceuticalUSA

Scancell granted orphan drug designation for melanoma drug

Scancell granted orphan drug designation for melanoma drug

17-02-2014

UK-based immunotherapy company Scancell has been granted orphan drug designation for its SCIB1 ImmunoBody…

ImmunologicalsOncologyPharmaceuticalRegulationScancellSCIB1UKUSA

AbbVie to spend $320 million to establish Singapore manufacturing presence

AbbVie to spend $320 million to establish Singapore manufacturing presence

06-02-2014

US drugmaker AbbVie says it plans to invest $320 million to establish operations in Singapore for small…

AbbVieAsia-PacificImmunologicalsOncologyPharmaceuticalProduction

IVO portfolio company Circassia plans to float on LSE

06-02-2014

The UK’s Imperial Innovations Group says that its largest portfolio company Circassia, has today announced…

Allergy TherapeuticsCircassiaFinancialImmunologicalsPharmaceutical

ALK’s 2013 annual report shows profit down but sales steady

ALK’s 2013 annual report shows profit down but sales steady

05-02-2014

Denmark-based allergy specialist ALK Abello (ALKB: DC) has released its annual report for 2013 recording…

ALK AbelloDenmarkFinancialImmunologicalsPharmaceutical

Medigene’s buy of Trianta is “lucrative move” say analysts

31-01-2014

Medigene’s 4 million euro ($5.5 million) purchase of fellow German company Trianta Immunotherapies…

FinancialImmunologicalsMedigeneMergers & AcquisitionsOncologyPharmaceuticalTrianta ImmunotherapiesUSA

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

FDA advisory panel backing for Merck/ALK ragweed allergy immunotherapy Ragwitek

28-01-2014

The US Food and Drug Administration’s Allergenic Products Advisory Committee has voted that the available…

Alk-AbelloImmunologicalsMerck & CoNorth AmericaPharmaceuticalRagwitekRegulationUSA

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

Gilead’s idelalisib shows promise in treating indolent non-Hodgkin lymphomas

24-01-2014

Slow-growing, or indolent, non-Hodgkin lymphomas are difficult to treat, with most patients relapsing…

BiotechnologyGilead SciencesidelalisibOncologyResearch

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

Isarna Therapeutics enters into a strategic manufacturing agreement with Sanofi

Isarna Therapeutics enters into a strategic manufacturing agreement with Sanofi

09-01-2014

German drug developer Isarna Therapeutics has signed a strategic manufacturing agreement with Sanofi…

FranceGermanyImmunologicalsIsarna TherapeuticsLicensingPharmaceuticalProductionSanofi

1 to 25 of 136 results

Back to top